Newsletter | February 20, 2024

02.20.24 -- How To Properly Evaluate Suppliers, Including Potential Risk

FEATURED EDITORIAL

How To Properly Evaluate Suppliers, Including Potential Risk

FDA 21 CFR 211 requires vendor qualification as a part of the validation process and EU GxP requirements expect robust vendor management, and we expect regulators to issue firmer guidance sooner rather than later. Don't let your company fall short.

INDUSTRY INSIGHTS

GxP Inventory Enhances Supply Chain For Global Specialty Biotech Firm

Discover how the simplification and digitization of clinical supply chain operations enhanced transparency, lowered risks and expenses, and optimized efficiency.

Effective Use Of IRT In Decentralized And Hybrid Clinical Trials

Uncover the ways interactive response technologies are helping trial sponsors manage the distribution of medications, forecast trial supply, and integrate workflows with other technology platforms.

My Worst Nightmare In RTSM: Accidental Unblinding

Learn how collaborative efforts from study managers, supply managers, biostatisticians, designers, and clinicians can better protect the blind in clinical trials and prevent accidental unblinding.

3 IRT Tactics Being Used To Streamline Supply Logistics

Shipping and storing leading-edge therapeutics require complex logistics, but enhanced automation and process simplification ensure that sites and patients have the drugs they need when they need them.

SOLUTIONS

Valor Glass: The Future Of Glass Packaging Is Here

An Agile, Accountable, And Transparent CDMO